Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

Abstract : Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders. Herein, we describe CD4+ T-cell changes over repeated cycles of rituximab and their relationship with clinical outcomes.
Complete list of metadatas

Cited literature [15 references]  Display  Hide  Download

https://hal-univ-tours.archives-ouvertes.fr/hal-01403387
Contributor : Denis Mulleman <>
Submitted on : Friday, November 25, 2016 - 7:40:55 PM
Last modification on : Thursday, February 7, 2019 - 4:13:27 PM
Long-term archiving on : Tuesday, March 21, 2017 - 4:15:19 AM

File

Lavielle ART 2016.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Matthieu Lavielle, Denis Mulleman, Philippe Goupille, Clément Bahuaud, Hsueh Cheng, et al.. Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. Arthritis Research & Therapy, BioMed Central, 2016, 58, pp.253. ⟨10.1186/s13075-016-1152-5⟩. ⟨hal-01403387⟩

Share

Metrics

Record views

106

Files downloads

125